What is claimed is:

1. A method for preparing a degradable tear duct plug, characterized by comprising first, putting a component A containing a polyethylene glycol derivative into a first material channel, and putting a component B containing a trilysine acetate into a second material channel; and then, extruding the component A from the first material channel and the component B from the second material channel, respectively, into a same mixing channel for static mixing to form a hydrogel, and heating and stretching the hydrogel after drying;

wherein, a speed ratio of the component A and the component B entering the mixing channel is (2 to 5):1, and a speed of the static mixing is 10 to 100 ml/min; and

the temperature for heating and stretching the hydrogel is 40°C to 80°C; and/or a stretching rate for heating and stretching the hydrogel is 0.2 to 2.0 m/s.

2. The method according to claim 1, wherein a speed ratio of the component A and the component B entering the mixing channel is (3 to 4): 1, and a speed of the static mixing is 30 to 60 ml/min.

3. The method according to claim 1 or claim 2, wherein the temperature for heating and stretching the hydrogel is 50°C to 70°C; and/or a stretching rate for heating and stretching the hydrogel is 0.6 to 1.2 m/s.

4. The method according to any one of claims 1 to 3, wherein the component A is a borax buffer containing the polyethylene glycol derivative with a concentration of 5% (w/v) to 40% (w/v).

5. The method according to any one of claims 1 to 4, wherein the component B is a borax buffer containing the trilysine acetate with a concentration of 1% (w/v) to 5% (w/v).

6. The method according to any one of claims 1 to 5, wherein a mass ratio of the polyethylene glycol derivative and the trilysine acetate is (20 to 50):1.

7. The method according to any one of claims 1 to 6, wherein the polyethylene glycol derivative is prepared by modifying polyethylene glycol by a group, and the group used for modifying polyethylene glycol is one or more selected from succinimidyl carbonate, succinimidyl glutarate, succinimidyl acetate, succinimidyl propionate, succinimidyl succinate, succinimidyl valerate, and maleimide.

8. The method according to any one of claims 1 to 7, wherein the component A and/or the component B respectively further comprises a chromogenic reagent, and the chromogenic reagent is preferably N-hydroxysuccinimidyl fluorescein.

9. The method according to any one of claims 1 to 8, wherein the component A and/or the component B respectively further comprises an ophthalmic drug, and the ophthalmic drug is preferably one or more selected from travoprost, latanoprost, cyclosporine, moxifloxacin, gatifloxacin, prednisolone, ibuprofen, dexamethasone, tobramycin, timolol, and atropine.

10. A degradable tear duct plug, characterized by being prepared by the method according to any one of claims 1 to 9,

wherein, the degradable tear duct plug has a diameter of 0.3 to 0.5 mm, and a length of 2 to 6 mm; and

after encountering water, the degradable tear duct plug expands to 0.8 to 2.0 mm in diameter; and is shortened in length by 10% to 60%.

11. The degradable tear duct plug according to claim 10, wherein the degradable tear duct plug has a diameter of 0.35 to 0.45 mm, and a length of 3 to 5 mm.

12. The degradable tear duct plug according to claim 10 or 11, wherein after encountering water, the degradable tear duct plug expands to 1.0 to 1.5 mm in diameter; and is shortened in length by 20% to 40%.

13. The degradable tear duct plug according to any one of claims 10 to 12, wherein the degradable tear duct plug comprises an ophthalmic drug, preferably the ophthalmic drug is one or more selected from travoprost, latanoprost, cyclosporine, moxifloxacin, gatifloxacin, prednisolone, ibuprofen, dexamethasone, tobramycin, timolol, and atropine.